CAS: 4021-50-5; 4-((Trifluoromethyl)Thio)Benzaldehyde

上下游产品

4-(trifluoromethylthio)benzyl bromide 4-[(trifluoromethyl)sulphanyl]benzenecarbonitrile 4-trifluoromethylthiotoluene 4-formylphenylboronic acid, 3-(4-trifluoromethylsulfanyl-phenyl)-acrylic acid (4-trifluoromethylthiophenyl)-oxirane -aethan1,2-Dibrom-1-4-trifluormethylmercapto-phenyl-aethan 1-ethenyl-4-[(trifluoromethyl)thio]benzene

4-(三氟甲硫基)苯甲基溴置于乌洛托品,溶剂黄146体系中,化学反应生成 对三氟甲硫基苯甲醛
参考文献:Marenets,M.S. Et Al.,Soviet Progress In Chemistry,1968,Vol. 34,# 9,P. 60-62
标题:Marenets,M.S. Et Al.,Soviet Progress In Chemistry,1968,Vol. 34,# 9,P. 60-62

专利信息

专利号:US-9446047-B2
优先权日:2013-09-10
标 题 :Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
发明人：VANKAYALAPATI HARIPRASAD; YERRAMREDDY VENKATAKRISHNAREDDY
权利人:ARRIEN PHARMACEUTICALS LLC
摘要:The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the Retinoic acid-related orphan nuclear receptor γt (RORγt)/RORγ. The compounds of the present invention are useful for modulating RORγt)/RORγ activity and for treating diseases or conditions mediated by RORγt)/RORγ such as for example, disease states associated with immunopathology of human autoimmune diseases such as Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Inflammatory Colitis, Psoriasis, COPD, Pain, Obesity, Diabetes, Dyslipidemia, Osteoporosis, Asthma, Neurodegenerative diseases and Cancer.